20/05/2024  21:59:55 Diferencia +0.52 Volumen Bid- Ask- Capitalización de mecado Dividendo A. P/E Ratio
16.81USD +3.16% 299,635
Volumen de negocios: 5.01 millones
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 19.04 mil millonesUSD - -

Descripción de negocio

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
 

Consejo de gestión & Consejo de supervisión

CEO
Kåre Schultz
Consejo de gestión
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs
Consejo de supervisión
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane
 

Datos de la empresa

Nombre: Teva Pharmaceuticals Industries Ltd.
Dirección: 5 Basel St.,Petach Tikva 49131, Israel
Teléfono: +972-3-914-8171
Fax: +972-3-914-8678
E-mail: -
Internet: www.tevapharm.com
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: 88.20%
Fecha de OPI: -

Relación con inversores

Nombre: Kevin C. Mannix
IR teléfono: +215-591-8912
IR-fax: -
IR e-mail: kevin.mannix@tevapharm.com

Accionistas mayoritarios

Freefloat
 
88.20%
Capital Research and Management Company
 
11.80%